Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for ASCT-related Symptom Burden in Multiple Myeloma
NCT05855122Phase 4Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in multiple myeloma (MM) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: MD Anderson Symptom Inventory and Adverse Events. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05855122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05855122.